Mass Tort Cases

 

What We Do

“Every case is prepared for victory at trial.  We litigate to win and will not be out-worked or out-fought in our pusuit for just compensation.”

 

Latest News on VIOXX Recall

April 27, 2005

Launched by Merck in 1999, VIOXX is a non-steroidal anti-inflammatory drug (“NSAID”) known as a COX-2 inhibitor. Due to Merck's aggressive promotion, VIOXX quickly became a hugely popular prescription pain reliever for the treatment of osteoarthritis, acute pain, menstrual pain and rheumatoid arthritis. Worldwide sales of VIOXX in 2003 were $2.5 billion.

The clinical trial leading to the withdrawal of VIOXX was not the first to raise suspicion about the safety of VIOXX. By early 2000, results from the VIGOR (VIOXX Gastrointestinal Outcomes Research) study also indicated an increased risk of cardiovascular events compared to another painkiller. The FDA sent a warning letter to Merck in 2001 calling Merck's promotional campaign for VIOXX “false and misleading” because it minimized the potentially serious findings in the VIGOR trial. Merck never put the cardiovascular risks associated with taking VIOXX in the Warning sections of the labeling for its multi-billion-dollar-a-year drug.

On September 30, 2004, FDA issued a Public Advisory to inform patients of Merck's actions and to advise them to see their doctors for alternative medications.

If you or your loved one has taken VIOXX and suffered a heart attack or stroke, you may want more information, you may wish to contact us. The attorneys at Paris & Chaikin, PLLC, are available to answer your questions. Consultations are free with no obligations. CALL OUR FIRM TODAY AT 212-742-0476.

Paris & Chaikin, PLLC is a New York based boutique personal injury law firm committed to representing innocent - Read More >
 
We are honored to represent a diverse client base in their quest for just compensation - Read More >
 
Paris & Chaikin, PLLC attorneys are experienced and aggressive, and represent those seriously injured - Read More >

Recent News & Current Events

Fri, 03 Feb 2012 16:48:00 -0800
Komen's Race To Reverse Course: Questions And A PR Challenge
The nation's largest breast cancer charity now says it will continue giving grants to Planned Parenthood. But public relations specialists say the Komen foundation will have a tough time rebuilding its nonpartisan reputation.

Fri, 03 Feb 2012 16:48:00 -0800
Contraception Provision Sets Off Firestorm
The Obama administration reaffirmed its position that certain religious institutions have to provide health coverage that offers free contraception. U.S. Catholic bishops are vowing to fight this rule in Congress, in courts, and in churches. Host Michel Martin speaks with Laurie Goodstein of the New York Times.

Fri, 03 Feb 2012 16:48:00 -0800
In Reversal, Komen To Continue Funding Planned Parenthood
Earlier this week, the foundation moved to discontinue funding of breast cancer screening by Planned Parenthood. The change came because of a new Komen policy forbidding forbidding grants to organizations under official investigation. Now that policy has been changed again.

Fri, 03 Feb 2012 16:48:00 -0800
Advocates Say Flu Vaccine Should Be Mandatory For Health Workers
A voluntary approach to flu vaccination of health care workers has fallen short. To protect patients, vaccination should be mandatory, consumer and business groups said in Washington. They back a requirement for annual vaccination of all health workers with only limited exemptions.

Fri, 03 Feb 2012 16:48:00 -0800
Komen Issues Apology In Planned Parenthood Flap
After a national backlash, the Komen for the Cure breast cancer foundation says it will continue its funding to Planned Parenthood. Earlier this week, Komen said it would cut support for affiliates of Planned Parenthood, which performs breast cancer screenings, amid an investigation by GOP lawmakers into Planned Parenthood and its funding of abortion services.